DANIEL COLLINS: Open Payments
NPI 1548247158 · LA JOLLA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$369 in 18 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $135 · 2025 $369
Food & beverage: $369
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 9 | $160 |
| AstraZeneca Pharmaceuticals LP | 3 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| Intercept Pharmaceuticals, Inc. | 1 | $25 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $24 |
| ORPHALAN INC | 1 | $17 |
| Madrigal Pharmaceuticals | 1 | $15 |
| Eurofins Viracor, LLC | 1 | $14 |
Products named: PREVYMIS, LIVTENCITY, OCALIVA, XIFAXAN, CUVRIOR, REZDIFFRA.
Industry payments across CA — which companies pay providers there.
